<DOC>
	<DOCNO>NCT02189148</DOCNO>
	<brief_summary>Preeclampsia complication pregnancy related adverse maternal neonatal outcome , include fetal growth restriction perinatal death . Several measure use investigation ( low-dose aspirin , low-molecular weight heparin , calcium , folic acid , among others ) prevention preeclampsia . Unfortunately , high-risk woman could benefit preventive measure identify late pregnancy . Recent evidence suggest investigator could identify woman risk develop preeclampsia use combination serum ultrasound biomarkers first-trimester pregnancy . This screening test need external validation . A first-trimester screening strategy strengthen clinical research preeclampsia contribute development strategy combine prediction prevention disease related complication .</brief_summary>
	<brief_title>First-trimester Prediction Preeclampsia</brief_title>
	<detailed_description>Background : Preeclampsia ( PE ) placenta-mediated pregnancy complication related adverse maternal neonatal outcome , include intra-uterine growth restriction ( IUGR ) perinatal death . A grow body evidence suggest preterm severe form PE associate deep placentation disorder occur early gestation . Over last decade , maternal characteristic first-trimester biomarkers , include already use aneuploidy screen ( PAPP-A ) strongly relate preterm early form PE , suggest early prediction possible . Preventive measure actually recommend ( low-dose aspirin ; calcium ) investigation ( folic acid ; low-molecular weight heparin ; anti-oxidant ) high-risk woman . However , woman chronic disease prior adverse pregnancy outcome eligible measure case PE occur nulliparous woman . Moreover , actually clear guideline clinician Canada whose pregnant patient one several risk factor preeclampsia ( obesity , chronic hypertension , low PAPP-A , etc. ) . On hand , suggest prediction PE , particularly severe case , possible high sensitivity specificity use combination anamnestic , biophysical , biochemical ultrasonographic biomarkers use web-based Fetal-Medicine Foundation ( FMF ) screen test . This suggest strategy prediction prevention PE placenta-mediated complication become possible nulliparous woman well . However , certain major concern must address : 1 ) The FMF screen test validate prospectively ; 2 ) controversy exists need feasibility Doppler ultrasound general population . Objectives : 1 . To validate 11-13 week FMF screen test early-onset PE composite placenta-mediated outcome ( preterm PE , IUGR &lt; 3rd percentile , stillbirth ) ; 2 . To compare screen test without uterine artery ( UtA ) Doppler ; 3 . To explore efficiency new potential biomarkers ( ADAM-12 ; Placental protein ( PP ) -13 ; placental subplacental volume ; placental vascularization ) prediction PE population . Methods : A multicenter prospective observational study nulliparous woman recruit 11 3/7 - 13 6/7 week ( maternal characteristic ; BMI ; Mean arterial pressure ( MAP ) ; PAPP-A ; placental growth factor ( PIGF ) ; UtA Doppler… ) follow delivery . Delivery neonatal data collect chart review . Detection rate early-onset PE ( primary outcome ) adverse pregnancy outcome measure use 11-13 week FMF screen test without UtA Doppler result . A case-cohort study perform use store serum sample three-dimensional ultrasound volume acquire 11-13 week visit . Feasibility power calculation : We estimate minimum incidence early-onset PE 0.7 % . A minimum 7,600 woman necessary demonstrate FMF screen test least 80 % sensitive 90 % specific expect 95 % sensitive 92 % specific . We power detect absolute difference 15 % detection rate different screening strategy ( ± Doppler ) . Recruitment take 3.0 year . The overall study take 5.0 year . Expectations : First , research potentially provide validate , highly sensitive specific , cheap tool help clinician ' decision care nulliparous woman risk factor PE . In case negative result , clinician good evidence reassure patient face abnormal maternal serum screen value . The validation first-trimester screen strategy strengthen clinical research PE provide new information natural evolution disease . Finally , study contribute develop optimal design randomize trial aim prevention early-onset PE placenta-mediated complication pregnancy .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<criteria>gestational age 11 3/7 13 6/7 week ; nulliparous woman ( previous delivery ≥ 20 week ) . pregnant woman &lt; 18 year old recruitment ; multiple pregnancy ; fetal congenital malformation ; positive HIV hepatitis C hepatitis B ; negative fetal heart recruitment ; woman plan delivery outside participate hospital ; woman able provide inform consent study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prediction</keyword>
	<keyword>Preeclampsia</keyword>
	<keyword>Preterm birth</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Placenta</keyword>
	<keyword>Intra-uterine growth restriction</keyword>
	<keyword>fetal growth restriction</keyword>
	<keyword>Ultrasound</keyword>
	<keyword>Doppler</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>PAPP-A</keyword>
	<keyword>Placental growth factor ( PlGF )</keyword>
</DOC>